rhinitis%20-%20allergic
RHINITIS - ALLERGIC
Allergic rhinitis is a symptomatic disorder of the nose secondary to IgE-mediated inflammation of the nasal membranes induced after exposure to allergens.
Major symptoms include nasal itching, watery rhinorrhea, nasal obstruction/congestion, sneezing and postnasal drainage.
Other symptoms include headache, conjunctival symptoms, eye pruritus, impaired smell and morning cough.
Symptoms can reverse spontaneous w/ or w/o treatment.

Patient Education

  • Provide general information about the disease and available treatments
    • Manage patient’s expectations from therapy and explain that a complete cure may not be possible
  • Provide educational materials as necessary
  • Educate patient about the proper use of medications and possible side effects
    • Concomitant medications should also be reviewed to determine if the patient is taking drugs that may cause oral or nasal dryness
  • Educate patient about the complications of allergic rhinitis (eg otitis media and chronic sinusitis)
  • Advise patient regarding the proper use and timing of medications during times when allergen exposure is unavoidable
  • Advise patient about lifestyle modification such as nasal irrigation with saline to clear the nose before sleeping and adjusting duration and time of sleep
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
23 Nov 2018
Initial acute respiratory illness (ARI) admissions related to human adenovirus (HAdV), human metapneumovirus (hMPV) and human rhinovirus (HRV) occurring during early infancy increase the risk of subsequent ARI-related readmission, a recent study has shown.
Jairia Dela Cruz, 08 Jan 2020
In chronic obstructive pulmonary disease (COPD) patients initiating inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, both budesonide/formoterol (FOR) dry-powder inhalers and beclomethasone/FOR metered-dose inhalers pose lower risks of severe pneumonia and severe adverse events compared with fluticasone/salmeterol delivered using the same type of inhaler, as reported in a recent study.
Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.

Pearl Toh, 03 Dec 2018
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.